Overview

A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy

Status:
Completed

Trial end date:
2009-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the clinical effectiveness and safety of golimumab intravenous (IV) infusions every 12 weeks with or without Methotrexate (MTX), compared with MTX alone, in patients with active rheumatoid arthritis (RA) despite concurrent MTX treatment. In addition, the safety of subcutaneous (SC) golimumab injections following transition from IV golimumab infusions will also be evaluated.

Phase:

Phase 3

Details

Lead Sponsor:

Centocor, Inc.

Collaborator:

Schering-Plough

Treatments:

Antibodies, Monoclonal
Golimumab
Methotrexate